Telix boosts in-house ra­dio­phar­ma man­u­fac­tur­ing; Dy­navax im­proves vac­cine pro­duc­tion costs

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

Telix Phar­ma­ceu­ti­cals is ac­quir­ing Texas-based ra­dio­phar­ma and bio­con­ju­gate com­pa­ny IsoTher­a­peu­tics in a deal that in­cludes $8 mil­lion up front. This will bring man­u­fac­tur­ing in-house for Aus­tralian biotech Telix, ac­cord­ing to a Tues­day re­lease.

Dy­navax Tech­nolo­gies tout­ed its de­creas­ing man­u­fac­tur­ing costs per unit for its he­pati­tis B vac­cine HEP­LISAV-B, at­tribut­ing this to “a num­ber of in­vest­ments in man­u­fac­tur­ing,” said CFO Kel­ly Mac­Don­ald dur­ing an in­vestor call on Feb. 22. The com­pa­ny made in­vest­ments at its anti­gen man­u­fac­tur­ing fa­cil­i­ty in Düssel­dorf, Ger­many, which has helped the com­pa­ny to im­prove its yield of HEP­LISAV-B.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER